Business Wire

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping

30.3.2026 11:00:00 CEST | Business Wire | Press Release

Share

The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/

Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London

Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport.

Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders.

World-class, immersive events will unfold across fourteen iconic international venues, spanning Europe, North America, and the Middle East inviting fans closer than ever to the grit, beauty, and power of high-stakes jumping.

The inaugural season will run from March to October 2027.

Designed to open the sport to new audiences whilst respecting its heritage, the PJL combines extraordinary athletic performance with premium entertainment, strengthened by the league’s partnership with Emmy award-winning production company Box to Box Films, and supported by a free-to-view broadcasting model. Cutting-edge technology, radical transparency, and innovative team formats enhance the drama, intensity, and rivalry that defines elite sport – unlocking the full potential of jumping, demanded by today’s global sports and entertainment marketplace, without compromising its core values.

With exceptional welfare standards, a pioneering development pathway, and financial sustainability at its core, the PJL is professionalising jumping.

This is elite sport.

This is extraordinary skill.

This is our sport as you’ve always loved it.

This is our sport as you’ve never seen it.

This is the PJL - the future of jumping.

Frank McCourt, Founder and Chairman of the PJL: “For far too long, many of the world’s best riders have been forced to choose between pursuing their talent and passion and building a sustainable career. The PJL is changing that by creating a clear and viable path for athletes to earn a great living by competing at the highest level, without compromising the traditions and values that define jumping. By aligning opportunity with performance and commitment, we are reshaping the future of the sport and empowering its most talented athletes to devote themselves fully to excellence.”

Neil Moffitt, Chief Executive Officer: “Today marks a major milestone for equestrian sport. The PJL has assembled an exceptional operations team to deliver on our mission to bring a new level of energy, excitement, and engagement to the sport.”

Lisa Lazarus, Chief Equestrian Advisor: “There is no greatness in horse sport without the welfare and safety of the horse. The PJL’s competition design, scheduling, travel approach, and veterinary oversight will reflect uncompromising standards of care, rest, and responsible decision-making every step of the way.”

Laura Kraut, Olympic gold medal-winning rider:“An Olympic gold medal is the greatest thing you can achieve in the sport. Yet for jumping athletes like me, the commercial opportunities often don’t follow. The gap between what athletes achieve and what they’re able to build tells you everything about the sport’s limited infrastructure to convert elite achievement into recognition and reward. I welcome the PJL’s values to reform this model in a way that drives revenue opportunities for all involved.”

Scott Brash, Olympic gold medal winner & current World Number 1 rider:With horses—and in our sport especially—learning never stops. One of my biggest goals is to help move the sport forward, creating a better environment for athletes, horses, everyone involved, and those who follow along. I believe the PJL gives us a meaningful platform to have these important conversations. Competing at the highest level comes with enormous costs, and for most riders, securing financial support while dedicating the necessary time to the sport is a constant balancing act.

What makes the PJL so impactful is that it rewards riders in a way that allows us to truly prioritize both our own well-being and that of our horses—making full-time training and proper rest possible. That’s something genuinely groundbreaking.”

About the Premier Jumping League (PJL)

The PJL is a new global showjumping competition redefining the sport through elite team competition, record-breaking prize money, and a sustainable professional model for riders. Backed by McCourt Global and shaped by leaders from equestrian sport, international competition, and entertainment, the PJL brings together the world’s top riders and horses to compete across fourteen iconic venues in Europe, North America, and the Middle East. With sixteen teams, an innovative rider selection process and a guaranteed $300 million prize pot, the PJL combines world-class athletic performance with premium entertainment, opening the sport to new global audiences while honouring its heritage.

About McCourt Global

McCourt Global is a diversified enterprise building for tomorrow across real estate and infrastructure, sports, technology, and media. With a global portfolio, the company combines operational expertise with strategic capital to develop impactful projects that create long-term economic and social value. Founded by Executive Chairman Frank McCourt, a civic entrepreneur and fifth-generation builder, and led by an international executive team, McCourt Global builds on a 133-year legacy of developing infrastructure and delivering strong financial results alongside a commitment to social impact—an approach that began with the McCourt family’s original company in Boston in 1893.

McCourt Global’s portfolio includes McCourt Partners, the real estate and infrastructure firm; Olympique de Marseille, the iconic Ligue 1 football club; the Premier Jumping League, a global showjumping competition redefining the sport; and Project Liberty, an initiative to build a better internet where individuals have greater control over their data in the era of AI. Headquartered in New York, McCourt Global operates across North America, Europe, and beyond. For more information, visit McCourt Global’s website or follow the company on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260330990938/en/

Contacts

The PJL: Kelly Hogarth | pressoffice@pjl.com - press@pjl.com​

McCourt Global: Anna Feagan | anna.feagan@mccourt.com

Follow the PJL today:
Website: www.pjl.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pjl.com&esh
eet=54468060&newsitemid=20260330990938&lan=en-US&anchor=www.pjl.com&index=7&md5=
73b90762776f0772a1751cec3624e334
Substack: @thepjl
Instagram: @the_pjl_official

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye